Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Supply chain

Government 'shortage protocols' should enable pharmacists to switch between branded drugs, say pharmacy leaders

Pharmacy organisations, including the Royal Pharmaceutical Society, have broadly approved a proposed amendment to the Human Medicines Regulation 2012.

Pharmacist holding a box of medicine


UK pharmacy organisations have called for assurances that a change in the law to help the problem of drug shortages would allow pharmacists to dispense different brands of the same medicine

Health legislation should be amended to allow pharmacists to switch between branded medicines in case of a medicines supply shortage, pharmacy leaders have said.

The Pharmaceutical Services Negotiating Committee (PSNC), the Company Chemists’ Association (CCA) and the Royal Pharmaceutical Society (RPS) have all broadly approved a proposed amendment to the Human Medicines Regulation 2012 which would allow pharmacists to dispense an alternative drug if the one prescribed to a given patient is in short supply.

The Department of Health and Social Care (DHSC) launched an urgent consultation with stakeholders on 7 December 2018 asking for their input into the use of “serious shortage protocols” (SSPs), which could see pharmacists respond to a shortage in one of four ways, including dispensing a reduced quantity, a therapeutic equivalent, a generic equivalent or an alternative dosage form.

However, the PSNC and CCA both called for assurance that substitutions could be made between branded medicines.

The PSNC said in its response that it was “not convinced that the current drafting permits the substitution of one branded or proprietary medicine for another, which may be vital”.

It continued: “It is also important that SSPs can be drafted to permit the substitution of a generic medicine against any branded medicine of the same active ingredient(s) — to ensure any local reliance on non-originator brands of medicines does not complicate the substitution of medicines/introduction of SSPs.”

The response from the CCA added: “We also believe that there should be provision made for substituting between branded medicines, as we can see occasions where this will be needed, such as switching between branded Salbutamol inhalers for patients with asthma.”

The RPS response also called for pharmacists to be given the option to make changes to the dosage of a patient’s drug where necessary.

The RPS’s consultation response said: “This could be necessary for example if a modified release form of a medicine were substituted for a standard release medicine or vice-versa which would require a dosage change in addition to quantity and dosage form change.”

The consultation closed on 12 December 2018, with the DHSC planning to put the amendment before Parliament in January 2019 as part of the ‘Human Medicines (FMD) (Amendment) Regulations 2019’.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205920

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.